Insulet develops, manufactures, and markets the Omnipod Insulin Management System for people that have diabetes. This system ...

Insulet Corporation (NASDAQ:PODD) reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the ...

Insulet forecasts total company revenue growth of 16%-20% for 2025, with Omnipod revenue growth projected at 17%-21%. U.S. Omnipod revenue is expected to grow 16%-20%, driven by the continued ramp-up ...

Tandem Diabetes Care, Inc.’s Control-IQ+ Technology, used with the t:slim and Mobi insulin pumps, becomes the second AID ...

Insulet (NASDAQ:PODD – Get Free Report) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research ...

The company produces and sells Omnipod, an automated insulin delivery device, which works without the need for external ...

Insulet’s Q4 revenue hit $597.5 million, up 17.2%, beating the $582.81 million consensus. Omnipod revenue climbed 16.9% to $585.7 million, with international sales up 33.5%. Get two weeks of ...

Stock analysts at Leerink Partnrs lowered their Q1 2025 earnings per share (EPS) estimates for Insulet in a research note ...

The company produces and sells Omnipod, an automated insulin delivery device, which works without the need for external tubing typically associated with conventional pumps and eliminates the need ...

Learn more about whether Koninklijke Philips N.V. or Insulet Corporation is a better investment based on AAII's A+ Investor ...

For the year ending December 31, 2025, the Company expects revenue growth of 16% to 20%. Revenue growth ranges by product line are: Total ...